SCHEMBL19869979

SCHEMBL19869979

O=C(c1ccc(Br)cc1)c1c(Cl)ncnc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
RAB9A P51151 3/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
AKR1C3 P42330 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
GSK3B P49841 2/20 0.39
TLR7 Q9NYK1 1/20 0.39
OGG1 O15527 1/20 0.38
EGFR P00533 1/20 0.38
HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL903214 0.80 ALDH1A1 (0.52) LMNACES2CES1RAB9AMAPT
SCHEMBL15524835 0.79 PDE4A (0.34) LMNAMAPK1SMN1; SMN2L3MBTL1
SCHEMBL19545066 0.74 MAPK13 (0.61) RAB9AMAPTMEN1MAPK1KMT2A
SCHEMBL17407850 0.74 SRD5A2 (0.57) RAB9AMEN1KMT2ANPC1
SCHEMBL132367 0.73 LMNA (0.73) LMNACES2CES1RAB9AMAPT
SCHEMBL3842531 0.73 LMNA (0.73) LMNACES2CES1RAB9AMAPT
SCHEMBL9126141 0.73 LMNA (0.73) LMNACES2CES1RAB9AMAPT
SCHEMBL3156716 0.73 MAPK1 (0.64) LMNACES2CES1RAB9AMAPT
SCHEMBL5305773 0.72 NAPRT (0.58) LMNACES2CES1RAB9AMAPT
SCHEMBL19533484 0.72 HPGD (0.47) LMNARAB9AMAPTNPC1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3265453-B1 NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 BOEHRINGER INGELHEIM INT (DE) 2022-06-29 EP disclosed
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-03 US disclosed
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-15 US disclosed
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BRD9, BRD1, BRD2 LMNA 1902/4885CES2 3963/4885CES1 2990/4885
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BRD9, BRD1, BRD2 LMNA 1745/4885CES2 3759/4885CES1 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.